Biologic May Be Effective For Patients With AD and Asthma
Dupilumab (Dupixent) effectively improved symptoms of atopic dermatitis (AD) among patients with comorbid asthma, according to the findings of a recent study.1
In the study, participants with AD with or without comorbid asthma were randomized to receive subcutaneous 300 mg of dupilumab every week (n=462) or every 2 weeks (n=457) or placebo (n= 460) for 16 weeks. The main outcomes of the study were the proportion of participants who achieved a 0/1 on the Investigator’s Global Assessment (IGA), a 75% or more improvement on the Eczema Area and Severity Index (EASI-75), a 4 point or more improvement on the peak pruritus Numerical Rating Scale (NRS), and safety.
Baricitinib Benefits Patients With Severe Atopic Dermatitis
Biologic Treatment Shows Improvement on Other Various Disease Severity Measures
Participants with or without comorbid asthma who were treated with dupilumab every 2 weeks or 1 week were more likely to achieve an IGA 0/1 (34.1% and 31.9% vs 9.3%, respectively), EASI-75 (50.0% and 47.4% vs 13.7%), and an improvement of 4 or more on NRS (37.9% and 37.8% vs 9.3%) at week 16 compared with those who received placebo.
In addition, adverse event rates were similar across treatment groups. The most frequently reported adverse events among participants treated with dupilumab were injection-site reactions and conjunctivitis.
“This subgroup analysis shows that dupilumab-treated patients with and without comorbid asthma have comparable [and] significant improvement in AD signs and symptoms,” the researchers concluded. “Future studies in AD patients with symptomatic comorbid asthma will help assess the potential benefit of dupilumab in both conditions.”
Following results from this study and other clinical trials, the FDA has accepted for review the supplemental Biologics License Application of dupilumab as an add-on maintenance therapy for certain adults and adolescents with moderate-to-severe asthma.2
1. Deleuran M, Guttman-Yassky E, Kingo K, et al. Dupilumab in moderate-to-severe atopic dermatitis with or without comorbid asthma: pooled analysis of 2 randomized phase 3 trials (LIBERTY AD SOLO 1 & 2). J Allergy Clin Immunol. 2018;141(2)(suppl): AB132. https://doi.org/10.1016/j.jaci.2017.12.420.
2. FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma [press release]. Sanofi: Paris and Tarrytown, NY, March 2, 2018. http://www.news.sanofi.us/FDA-to-review-Dupixent-R-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma. Accessed March 5, 2018.